Teladoc Health financials
$5.75−2.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.57B | $2.60B | $2.41B | $2.03B | $1.09B | $553.3M | $417.9M | $233.3M | $123.2M |
| Gross profit | $1.76B | $1.82B | $1.84B | $1.66B | $1.38B | $703.1M | $368.8M | $289.2M | $171.7M | $91.2M |
| Gross margin | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | 64.3% | 66.7% | 69.2% | 73.6% | 74.0% |
| Operating income | -$263.0M | -$1.02B | -$248.6M | -$13.65B | -$265.6M | -$506.4M | -$80.4M | -$76.4M | -$75.4M | -$62.7M |
| Net income | -$200.3M | -$1.00B | -$220.4M | -$13.66B | -$428.8M | -$485.1M | -$98.9M | -$97.1M | -$106.8M | -$74.2M |
| Net margin | −7.9% | −39.0% | −8.5% | −567.5% | −21.1% | −44.3% | −17.9% | −23.2% | −45.8% | −60.3% |
| Diluted EPS | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 | $-1.38 | $-1.47 | $-1.93 | $-1.75 |
| EBITDA | $200.7M | $164.8M | $126.6M | $28.7M | -$19.4M | -$347.0M | -$34.9M | -$30.4M | -$29.0M | -$35.6M |
| Operating cash flow | $294.4M | $293.7M | $350.0M | $189.3M | $194.0M | -$53.5M | $29.9M | -$4.9M | -$34.4M | -$51.9M |
| Free cash flow | $166.9M | $169.6M | $193.7M | $16.5M | $130.1M | -$79.6M | $26.4M | -$8.9M | -$37.1M | -$54.0M |
| Diluted shares | 176.2M | 170.6M | 164.6M | 161.5M | 156.9M | 90.5M | 71.8M | 65.8M | 55.4M | 42.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $781.1M | $1.30B | $1.12B | $918.2M | $893.5M | $733.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.5M | $53.2M |
| Total debt | $994.9M | $1.54B | $1.54B | $1.54B | $1.25B | $1.45B |
| Total assets | $2.86B | $3.52B | $4.39B | $4.35B | $17.73B | $17.76B |
| Total liabilities | $1.47B | $2.03B | $2.07B | $2.04B | $1.69B | $1.87B |
| Shareholders' equity | $1.39B | $1.49B | $2.33B | $2.31B | $16.05B | $15.88B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology